<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02992483</url>
  </required_header>
  <id_info>
    <org_study_id>CMIK665X2101</org_study_id>
    <secondary_id>2016-003624-22</secondary_id>
    <nct_id>NCT02992483</nct_id>
  </id_info>
  <brief_title>Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma</brief_title>
  <official_title>Phase I Open Label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacokinetics of Intravenously Administered MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first in human study is to assess safety, tolerability, PK and
      preliminary clinical activity and to estimate the MTD(s)/RDE(s) of MIK665 (also referred as
      S64315) as single agent administered intravenously (i.v.) in adult patients with refractory
      or relapsed lymphoma or multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The design of this phase I, open label, dose finding study was chosen in order to
      characterize the safety and tolerability of MIK665 and to determine the Maximal Tolerated
      Dose(s) (MTD(s)) and/or Recommended Dose(s) for Expansion (RDE(s)).

      This study will utilize a Bayesian Hierarchical model to guide dose escalation and estimate
      the MTD(s) based on the dose-DLT relationship(s) for MIK665 in the indications.

      The expansion part of the study will employ an open-label multiple arm design. The purpose of
      the expansion part is to further assess safety, tolerability, PK, PD and the anti-tumor
      activity of MIK665 at the selected RDE/s for Multiple Myeloma (MM) and MYC positive Diffuse
      large B-Cell Lymphoma (DLBCL) identified in the dose-escalation part.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2017</start_date>
  <completion_date type="Anticipated">July 13, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 4, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of AEs and SAEs, incl. changes in laboratory parameters, vital signs and ECGs.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of DLTs during the first cycle of treatment with single agent MIK665 during the dose escalation phase only</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability: Dose interruptions</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability: Dose reductions</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability: Dose intensity</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Overall response (BOR) per International Myeloma Working Group (IMWG) criteria for Myeloma; and per revised criteria for staging of the International Working Group (IWG) guidelines for Lymphoma</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>2 years</time_frame>
    <description>Plasma PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>2 years</time_frame>
    <description>Plasma PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (T1/2)</measure>
    <time_frame>2 years</time_frame>
    <description>Plasma PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz)</measure>
    <time_frame>2 years</time_frame>
    <description>Plasma PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>2 years</time_frame>
    <description>Plasma PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)per International Myeloma Working Group (IMWG) criteria for Myeloma; and per revised criteria for staging of the International Working Group (IWG) guidelines for Lymphoma</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) criteria for Myeloma; and per revised criteria for staging of the International Working Group (IWG) guidelines for Lymphoma</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma</condition>
  <arm_group>
    <arm_group_label>MIK665</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MIK665</intervention_name>
    <description>MIK665</description>
    <arm_group_label>MIK665</arm_group_label>
    <other_name>S64315</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Age â‰¥ 18 years.

          -  Histologically confirmed lymphoma (WHO classification), or confirmed MM (IMWG), that
             is relapsed and/or refractory.

          -  Other Inclusion Criteria May Apply.

        Exclusion Criteria

          -  Known history of chronic liver disease

          -  History of chronic pancreatitis.

          -  Prior treatment with Mcl-1 inhibitor.

          -  Other Exclusion Criteria May Apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla Y Leon</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2016</study_first_submitted>
  <study_first_submitted_qc>December 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2016</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>lymphoma</keyword>
  <keyword>dlbcl</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

